0000950170-24-024006.txt : 20240301 0000950170-24-024006.hdr.sgml : 20240301 20240301170206 ACCESSION NUMBER: 0000950170-24-024006 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240228 FILED AS OF DATE: 20240301 DATE AS OF CHANGE: 20240301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MACAN WILLIAM ANDREW CENTRAL INDEX KEY: 0001758584 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38546 FILM NUMBER: 24711316 MAIL ADDRESS: STREET 1: 24275 KATY FREEWAY, SUITE 600 CITY: KATY STATE: TX ZIP: 77494 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Neuronetics, Inc. CENTRAL INDEX KEY: 0001227636 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3222 PHOENIXVILLE PIKE CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 877-600-7555 MAIL ADDRESS: STREET 1: 3222 PHOENIXVILLE PIKE CITY: MALVERN STATE: PA ZIP: 19355 FORMER COMPANY: FORMER CONFORMED NAME: NEURONETICS INC DATE OF NAME CHANGE: 20030416 4 1 ownership.xml 4 X0508 4 2024-02-28 0001227636 Neuronetics, Inc. STIM 0001758584 MACAN WILLIAM ANDREW C/O NEURONETICS, INC. 3222 PHOENIXVILLE PIKE MALVERN PA 19355 false true false false EVP, GC, CCO and CS false Common Stock 2024-02-28 4 S false 22377 3.16 D 395359 D Common Stock 2024-02-29 4 S false 6026 2.94 D 389333 D Common Stock 2024-02-29 4 A false 15000 0 A 404333 D The sales reported in this Form 4 were non-discretionary sales to satisfy the Reporting Person's tax withholding obligation upon vesting of a portion of a restricted stock unit ("RSU") award. The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $2.95 to $3.31. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $2.77 to $3.14. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Represents a RSU award that vests in three equal annual installments beginning on February 28, 2025, in each case subject to continuous service of the Reporting Person through such date. Each RSU represents a contingent right to receive one share of the Issuer's common stock. /s/ W. Andrew Macan 2024-03-01